FDA Will Issue Multiple Drug Decisions This October
The FDA is scheduled to finalize key regulatory reviews for cancer and eye disease treatments throughout October 2026.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Will the FDA approve upcoming drug applications for Roche, Viatris, and Opus Genetics this October?
Throughout October 2026, the FDA will issue regulatory decisions for several new drug applications, including potential therapies for colon cancer and thyroid eye disease. These outcomes follow a rigorous review process that recently saw Merck withdraw its application for Ifinatamab Deruxtecan.
Why it matters
These upcoming decisions represent critical milestones for patients waiting for new treatment options for colon cancer, thyroid eye disease, and presbyopia. The results will determine the availability of therapies that have shown significant clinical promise in recent trials.
The ATOMIC study enrolled 712 patients to evaluate Tecentriq for stage III colon cancer, while the SatraGO-2 trial reported 53% of Enspryng patients achieved improvement in eye bulging. These figures are part of the evidence supporting upcoming FDA regulatory reviews.
The players
FDA
The federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs.
Merck
A multinational pharmaceutical company that researches and markets therapies for oncology and infectious diseases.
Roche
A global healthcare company focused on diagnostics and pharmaceuticals, particularly in the fields of oncology and immunology.
The details
The FDA evaluates drug applications through the PDUFA target deadline process, where it assesses safety and efficacy data to determine whether a treatment should be approved or rejected via a Complete Response Letter. In cases like Ifinatamab Deruxtecan, the agency may determine that provided data is insufficient to meet the specific requirements for accelerated approval.
Timeline
September 25, 2026: Merck withdrew its application for Ifinatamab Deruxtecan.
October 9, 2026: FDA decision expected on Tecentriq for stage III colon cancer.
October 15, 2026: FDA decision expected on Enspryng for thyroid eye disease.
October 17, 2026: FDA decision expected on MR-141 for presbyopia.
Health Landscape
These upcoming decisions operate within the FDA PDUFA target deadline process, which governs the systematic review of new pharmaceutical applications. This cycle reflects the broader trend of evaluating targeted therapies for chronic and malignant conditions based on phase 3 trial results.
If you are managing stage III colon cancer or thyroid eye disease, these regulatory updates may eventually influence the availability of new treatment options. Discuss how these potential new therapies might align with your current care plan with your physician.
The takeaway
The FDA is moving toward a series of key drug decisions that could expand treatment options for specific cancer and eye conditions. Patients should follow the outcomes of these reviews and consult their physician regarding whether these developments change their current treatment conversation.
Further reading
For broader context on current clinical advancements, visit our Cancer section.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Will the FDA approve upcoming drug applications for Roche, Viatris, and Opus Genetics this October?
